Bristol-Myers Squibb Company with ticker code (BMY) now have 21 confirmed analysts covering the stock with the consensus suggesting a rating of ‘buy’. The range between the high target price and low target price is between $90.00 and $55.00 calculating the mean target price we have $71.57. Now with the previous closing price of $51.53 and the analysts are correct then we can expect a percentage increase in value of 38.9%. Also worth taking note is the 50 day moving average now sits at $58.21 and the 200 moving average now moves to $64.85. The company has a market capitalization of 104.90B. The stock price for the company is currently $51.56 USD
The potential market cap would be $145,698,422,348 based on the market consensus.
The company is not paying dividends at this time.
Other points of data to note are a P/E ratio of 13.09, revenue per share of $21.51 and a 5.59% return on assets.
Bristol-Myers Squibb Company is a biopharmaceutical company. The Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution, and sale of biopharmaceutical products. It offers products for a range of therapeutic classes, which include oncology, immunology, cardiovascular and hematology. Its pharmaceutical products include chemically synthesized or small molecule drugs and products produced from biological processes, called biologics. Biologics are administered to patients through injections or by infusion. Its products include Revlimid, Abecma, Eliquis, Opdivo, Orencia, Pomalyst/Imnovid, Sprycel, Yervoy, Abraxane, Empliciti, Reblozyl, Inrebic, Onureg, Zeposia, Camzyos, and Breyanzi. It also has a pipeline of investigational medicines designed to target the common mutations associated with oncogenesis, including repotrectinib. Its products are sold to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies.
